Synopsis
Synopsis
0
EU WC
0
KDMF
0
VMF
0
FDA Orange Book
0
Europe
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Acetate, Lysine
2. Enisyl
3. L Lysine
4. L-lysine
5. Lysine
6. Lysine Acetate
7. Lysine Hydrochloride
1. 657-27-2
2. L-lysine Monohydrochloride
3. Lysine Hydrochloride
4. L-lysine, Monohydrochloride
5. 10098-89-2
6. H-lys-oh.hcl
7. L-(+)-lysine Monohydrochloride
8. L-lysine Hcl
9. (s)-2,6-diaminohexanoic Acid Hydrochloride
10. Lysine Hcl
11. Lyamine
12. L-lysine Monohydrocholoride
13. L-lysinehydrochloride>99%
14. Lysine Hcl, L-
15. Darvyl
16. Enisyl
17. Lysion
18. (2s)-2,6-diaminohexanoic Acid Hydrochloride
19. L-gen
20. Jnj23q2com
21. Poly(l-lysine) Hydrochloride
22. Lysine, L-, Monohydrochloride
23. Lysine, Monohydrochloride
24. Chebi:53633
25. Nsc-9253
26. Mfcd00064564
27. L-lysine, Hydrochloride
28. (s)-2,6-diaminohexanoic Acid Hydrochloride(1:x)
29. (2s)-2,6-diaminohexanoic Acid;hydrochloride
30. Lysine Hydrochloride (van)
31. 28826-16-6
32. L-lysine Hydrochloride (van)
33. Lysine, Monohydrochloride, L-
34. L-lysine, Hydrochloride (1:?)
35. Nsc 9253
36. Einecs 211-519-9
37. Unii-jnj23q2com
38. L(+)-lysine Monohydrochloride
39. Ai3-52405
40. (s)-2,6-diaminohexanoic Acid Monohydrochloride
41. Einecs 233-234-9
42. Lysine Hydrochloride [usan:usp:jan]
43. L-lysine.hydrochloride
44. H-lys-oh⋅hcl
45. H-lys-oh?cl
46. L-lysine-hydrochloride
47. Lysine Hcl [inci]
48. Ec 211-519-9
49. Lysine Hydrochloride (usp)
50. L-lysine Hydrochloride,(s)
51. Schembl41761
52. L-lysine Hydrochloride Solution
53. L(+)-lysine Monohy-drochloride
54. Chembl2105886
55. Dtxsid9029198
56. L-lysine Hydrochloride (jp17)
57. L-lysine, Hydrochloride (1:1)
58. Lysine Hydrochloride [jan]
59. Pharmakon1600-01301003
60. Lysine Hydrochloride [usan]
61. Hy-n0470
62. Lysine Hydrochloride [vandf]
63. L-lysine Hydrochloride [jan]
64. Lysine Hydrochloride [mart.]
65. Lysine Monohydrochloride [mi]
66. Nsc760110
67. S3953
68. Lysine Hydrochloride [who-dd]
69. Akos015847945
70. Akos015892881
71. Am81901
72. Ccg-214725
73. Cs-7885
74. Nsc-760110
75. L-lysine Hydrochloride [usp-rs]
76. L-lysine Monohydrochloride [fcc]
77. Ac-23978
78. Bs-17408
79. Lysine Hydrochloride [ep Monograph]
80. Db-029969
81. L-lysine Monohydrochloride, P.a., 98.5%
82. Lysine Hydrochloride [usp Monograph]
83. L0071
84. L-lysine Hydrochloride, >=98%, Natural, Fg
85. Lysine Hydrochloride (l-lysine Hydrochloride)
86. D02279
87. D70613
88. M03093
89. 657l272
90. A800311
91. J-521652
92. L-alpha,epsilondiaminocaproic Acid Monohydrochloride
93. Q-100750
94. L-lysine Monohydrochloride, Bioultra, >=99.5% (at)
95. Q27124123
96. Z940713328
97. L-lysine Monohydrochloride, Reagent Grade, >=98% (hplc)
98. L-lysine Monohydrochloride, Saj Special Grade, >=99.0%
99. L-lysine Monohydrochloride, Vetec(tm) Reagent Grade, >=98%
100. H-lys-oh.hcl L-lysine Monohydrochloride (from Non-animal Source)
101. L-lysine Monohydrochloride, Cell Culture Reagent (h-l-lys-oh.hcl)
102. Lysine Hydrochloride, European Pharmacopoeia (ep) Reference Standard
103. L-lysine Hydrochloride, United States Pharmacopeia (usp) Reference Standard
104. L-lysine Monohydrochloride, Certified Reference Material, Tracecert(r)
105. L-lysine Hydrochloride Solution, 100 Mm Amino Acid In 0.1 M Hcl, Analytical Standard
106. L-lysine Monohydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
107. L-lysine Monohydrochloride, From Non-animal Source, Meets Ep, Jp, Usp Testing Specifications, Suitable For Cell Culture, 98.5-101.0%
108. L-lysine Monohydrochloride, Pharmagrade, Ajinomoto, Ep, Jp, Usp, Manufactured Under Appropriate Gmp Controls For Pharma Or Biopharmaceutical Production, Suitable For Cell Culture
Molecular Weight | 182.65 g/mol |
---|---|
Molecular Formula | C6H15ClN2O2 |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 5 |
Exact Mass | 182.0822054 g/mol |
Monoisotopic Mass | 182.0822054 g/mol |
Topological Polar Surface Area | 89.3 Ų |
Heavy Atom Count | 11 |
Formal Charge | 0 |
Complexity | 106 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
27
PharmaCompass offers a list of L-Lysine Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right L-Lysine Hydrochloride manufacturer or L-Lysine Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred L-Lysine Hydrochloride manufacturer or L-Lysine Hydrochloride supplier.
PharmaCompass also assists you with knowing the L-Lysine Hydrochloride API Price utilized in the formulation of products. L-Lysine Hydrochloride API Price is not always fixed or binding as the L-Lysine Hydrochloride Price is obtained through a variety of data sources. The L-Lysine Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Lyamine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lyamine, including repackagers and relabelers. The FDA regulates Lyamine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lyamine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Lyamine manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Lyamine supplier is an individual or a company that provides Lyamine active pharmaceutical ingredient (API) or Lyamine finished formulations upon request. The Lyamine suppliers may include Lyamine API manufacturers, exporters, distributors and traders.
click here to find a list of Lyamine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Lyamine DMF (Drug Master File) is a document detailing the whole manufacturing process of Lyamine active pharmaceutical ingredient (API) in detail. Different forms of Lyamine DMFs exist exist since differing nations have different regulations, such as Lyamine USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Lyamine DMF submitted to regulatory agencies in the US is known as a USDMF. Lyamine USDMF includes data on Lyamine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lyamine USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Lyamine suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Lyamine Drug Master File in Japan (Lyamine JDMF) empowers Lyamine API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Lyamine JDMF during the approval evaluation for pharmaceutical products. At the time of Lyamine JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Lyamine suppliers with JDMF on PharmaCompass.
A Lyamine CEP of the European Pharmacopoeia monograph is often referred to as a Lyamine Certificate of Suitability (COS). The purpose of a Lyamine CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Lyamine EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Lyamine to their clients by showing that a Lyamine CEP has been issued for it. The manufacturer submits a Lyamine CEP (COS) as part of the market authorization procedure, and it takes on the role of a Lyamine CEP holder for the record. Additionally, the data presented in the Lyamine CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Lyamine DMF.
A Lyamine CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Lyamine CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Lyamine suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Lyamine as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Lyamine API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Lyamine as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Lyamine and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Lyamine NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Lyamine suppliers with NDC on PharmaCompass.
Lyamine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lyamine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lyamine GMP manufacturer or Lyamine GMP API supplier for your needs.
A Lyamine CoA (Certificate of Analysis) is a formal document that attests to Lyamine's compliance with Lyamine specifications and serves as a tool for batch-level quality control.
Lyamine CoA mostly includes findings from lab analyses of a specific batch. For each Lyamine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lyamine may be tested according to a variety of international standards, such as European Pharmacopoeia (Lyamine EP), Lyamine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lyamine USP).